Symbio Pharmaceuticals Ltd operates in the Commercial physical research sector.
In addition to historical fundamental analyses, the complete report available to purchase compares Symbio Pharmaceuticals Ltd with three other
companies in this sector in Japan:
Medical Data Vision Co Ltd
(2018
sales of 3.58 billion Japanese Yen [US$32.34 million]
),
Trans Genic Inc
(3.60 billion Japanese Yen [US$32.56 million]
of which 42%
was TGBS business), and
GNI Group Limited
(5.02 billion Japanese Yen [US$45.37 million]
).

Sales Analysis.
Symbio Pharmaceuticals Ltd reported sales of ¥3.84 billion (US$34.67 million)
for the
year ending
December of 2018.
This
represents
an
increase of 11.4%
versus 2017, when the company's sales were ¥3.44 billion.
This was the third consecutive year of growth at Symbio Pharmaceuticals Ltd.